NCT06618105View on ClinicalTrials.gov

Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Mild Asthma
Interventions
DRUG

Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations

Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.)

DRUG

Test Placebo

Matching Placebo of T inhalation aerosol

DRUG

Reference Placebo

Matching Placebo of R inhalation aerosol

DRUG

Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations

Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (distributed by Teva Pharmaceuticals USA, Inc.)

Trial Locations (1)

Unknown

Multiple Locations, Multiple Locations

Sponsors
All Listed Sponsors
lead

Macleods Pharmaceuticals Ltd

INDUSTRY

NCT06618105 - Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd | Biotech Hunter | Biotech Hunter